Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 4,41,03,761 contracts with a turnover of Rs.27,99,622.77 crore.

Index trend and stocks in action August 02, 2019
Index trend and stocks in action August 02, 2019

Index trend and stocks in action August 02, 2019

DSIJ Intelligence Article rating: 4.7

It is advisable to wait until Nifty moves above the 200-DMA, which is currently placed at 11,150 level, to get confirmation of the short-term strength. The next support level is placed at 61.8 per cent retracement of Oct-June rally at 10,806. Stocks in news: PSP Projects, National Aluminium, Allahabad Bank, Bank of India, Power Grid, Adani Transmission, SRF, Wipro.

NCC bags orders worth over Rs. 500 crore in July
NCC bags orders worth over Rs. 500 crore in July

NCC bags orders worth over Rs. 500 crore in July

Apurva Joshi Article rating: 3.2

NCC Limited has bagged two new orders worth Rs 503.80 crore in the month of July 2019. These orders are received from the central and state government agencies.

Quarterly Results to watch out on August 2
Quarterly Results to watch out on August 2

Quarterly Results to watch out on August 2

DSIJ Intelligence Article rating: 4.0

The following stocks would be in focus during Friday’s trading session in light of their results announcement: Nestle India, Inox Leisure, HDFC Limited, ITC and Bata India.


Market Close: Sensex dips 462.8 points as Fed cuts rate
Market Close: Sensex dips 462.8 points as Fed cuts rate

Market Close: Sensex dips 462.8 points as Fed cuts rate

DSIJ Intelligence Article rating: 5.0

Despite a decent recovery in the last trading session, the benchmark indices failed to close in the green zone. The BSE Sensex dipped by 462.80 points or 1.23 per cent at 37,018.32 on Thursday on the back of negative global cues as the US Fed cut benchmark policy rate.

Biocon launches biosimilar trastuzumab in Australia
Biocon launches biosimilar trastuzumab in Australia

Biocon launches biosimilar trastuzumab in Australia

Amir Shaikh Article rating: 5.0

Biocon informed the bourses that the company along with Mylan has launch Ogivri (trastuzumab), a biosimilar to Herceptin1, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) in Australia.

RSS
First31743175317631773179318131823183Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR